Patients

WU-CART-007 is an investigational, off the shelf, fratricide-resistant allogeneic CD7 targeted CAR-T cell being evaluated in a Phase 1/2 study of adolescent and adult patients with relapsed or refractory (R/R) T cell acute lymphoblastic leukemia/ Lymphoma (T-ALL/LBL).  All patients who receive WU-CART-007 will transition to a separate study for long-term follow-up, up to 15 years after infusion of WU-CART-007.

For more information, visit www.clinicaltrials.gov, study identifier number NCT04984356